- |||||||||| safimaltib (JNJ-6633) / J&J
Journal: Targeting MALT1 in B-cell Lymphomas. (Pubmed Central) - Nov 7, 2026 Safimaltib, a selective allosteric MALT1 protease inhibitor, shows potent antitumor activity in preclinical and clinical studies of B-cell non-Hodgkin lymphomas. See related article by Philippar et al., p. XX See related article by Hertzberg et al., p. XX.
- |||||||||| Helper T cell immune synapse drives alternative survival programs and tumor heterogeneity in diffuse large B-cell lymphomas (MCCNO - Hall F) - Nov 4, 2026 - Abstract #ASH2026ASH_4637;
These findings demonstrate how TME-derived signals outside of mutations can act as a selective pressure favoring the emergence of malignant B cell states resistant to single-agent therapies. Further, this work provides a framework for leveraging programmable organoids to model biophysical and cellular TME interactions for developing effective microenvironment-informed therapeutic strategies targeting both tumor-intrinsic and TME-dependent survival dependencies.
- |||||||||| Calquence (acalabrutinib) / AstraZeneca
Losing a brake creates a target: TOX is a tumor suppressor whose loss confers NF-?B addiction in ABC-DLBCL (MCCNO - New Orleans Theatre A) - Nov 4, 2026 - Abstract #ASH2026ASH_1895; In a cell viability screen of 20 compounds targeting distinct NF-?B pathway components and upstream regulators, the BTK inhibitor acalabrutinib and the MALT1 inhibitor JNJ-67690246 were 2-3-fold more active against TOX deficient than isogenic parent TMD8 cells...Using orthogonal human and murine approaches, we establish TOX as a bona fide tumor-suppressor in ABC-DLBCL whose loss drives NF-?B-dependent tumor-intrinsic aggression and a pro-tumoral, immunosuppressive LME. The preferential sensitivity of TOX-deficient lymphoma to BTK and MALT1 inhibition nominates TOX loss-of-function as an actionable biomarker for therapeutic stratification of high-risk MCD/C5 DLBCL patients.
- |||||||||| Brukinsa (zanubrutinib) / BeOne Medicines, Calquence (acalabrutinib) / AstraZeneca, Imbruvica (ibrutinib) / AbbVie, J&J
The protease MALT1 is required for chronic lymphocytic leukemia genesis in E?-TCL1 mice (Section 32) - Mar 17, 2026 - Abstract #AACR2026AACR_10063; Our data concerning the dermatopathological complications associated with the E?-TCL1-/-/MALT1-/- and E?-TCL1wt/MALT1-/- cohorts highlights potential side effects of MALT1 inhibition and are of note due to the frequent clinical presentation of cutaneous lesions in CLL patients. Overall, our data suggest that MALT1 is required for CLL leukemogenesis and may represent a critical component in therapeutic targeting.
- |||||||||| safimaltib (JNJ-6633) / J&J
Review, Journal: Therapeutic targeting of MALT1 in oncology: Mechanism, inhibitor development, and clinical prospects. (Pubmed Central) - Mar 5, 2026 However, MALT1-targeted therapy poses a dual challenge: although inhibiting oncogenic signaling and tumor cell proliferation, it also disrupts immunosuppressive Treg function, risking autoimmune toxicity by compromising the tumor microenvironment. This review systematically analyzes MALT1's oncogenic roles across cancers, clarifies inhibitor mechanisms, and evaluates translational challenges and strategic opportunities for precision oncology and combination immunotherapy.
- |||||||||| Journal: Novel Compounds as MALT1 Inhibitors for Treating Cancer. (Pubmed Central) - Feb 18, 2026
This review systematically analyzes MALT1's oncogenic roles across cancers, clarifies inhibitor mechanisms, and evaluates translational challenges and strategic opportunities for precision oncology and combination immunotherapy. Provided herein are novel compounds as MALT1 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.
- |||||||||| thioridazine / Generic mfg.
Journal: In silico study of some plant compounds as potential anticancer agents targeting MALT1 allosteric domain. (Pubmed Central) - Jan 29, 2026 Our findings from this computational study presents cyanidin (-8.822 kcal/mol) as better binder to the allosteric site of MALT1 based on the molecular docking and pharmacokinetic profiling than thioridazine...Hence, cyanidin is a potential allosteric inhibitor of MALT1. However, an urgent need for in vitro and in vivo validations is required to ascertain the efficacy of cyanidin in the fight against cancer and other MALT1-related diseases.
- |||||||||| SGR-1505 / Schrodinger, Noxafil (posaconazole) / Merck (MSD)
P1 data, PK/PD data, Journal: A Phase 1 Dose-Escalation, Food Effect, and Drug-Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR-1505, in Healthy Volunteers. (Pubmed Central) - Jan 19, 2026 Co-administration with posaconazole increased SGR-1505 exposure 3-fold...Asymptomatic, reversible indirect hyperbilirubinemia occurred, consistent with inhibition of UGT1A1. SGR-1505 was well-tolerated and exhibited favorable pharmacokinetic and pharmacodynamic properties, supporting further clinical development.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie
MALT1 inhibitor suppresses AML by inducing MCPIP1 expression and shows synergy with venetoclax () - Dec 5, 2025 - Abstract #ASH2025ASH_8746; Next, we will conduct experiments testing this drug combination on normal human CD34+ cells and determine the optimal therapeutic concentration required for effective eradication of leukemia cells. This work will yield critical preclinical data to support future clinical translation.
- |||||||||| Jakafi (ruxolitinib) / Incyte, safimaltib (JNJ-6633) / J&J
Case study: Novel CARD11 gain-of-function mutation in patient with T-LGL leukemia and autoimmunity (A / B (Confex)) - Nov 5, 2025 - Abstract #DGHO2025DGHO_1199; Analysis of the patient's primary T cells revealed upregulated cytokine and inflammatory pathways, with a shift toward an effector memory phenotype confirmed via surface marker staining.Next, we evaluated the impact of immunosuppressive drugs targeting NF?B and cytokine signaling, including dimethylfumarate (NF?B inhibitor), safimaltib (MALT1 inhibitor), and ruxolitinib (JAK inhibitor)...Functional assays using an NF?B reporter cell line and primary T cells confirmed its role in T cell activation. We also demonstrate that targeted MALT1 inhibition effectively reduces NF?B signaling in this context, supporting its potential for therapeutic intervention.
- |||||||||| SGR-1505 / Schrodinger
SGR-1505, a potent and selective MALT1 inhibitor with preliminary efficacy in BTKi exposed Waldenstr (OCCC - West Halls B3-B4) - Nov 4, 2025 - Abstract #ASH2025ASH_4559; P1 Clinically, SGR-1505 demonstrated encouraging anti-tumor activity in prior BTKi exposedWM, BTKi/BCL2i double-exposed CLL/SLL and other B-cell malignancies. MALT1 inhibition represents apromising novel therapeutic option with broad activity across multiple tumor types and the potential toovercome BTK and BCL2 resistance.
- |||||||||| SGR-1505 / Schrodinger
Journal: Accelerated In Silico Discovery of SGR-1505: A Potent MALT1 Allosteric Inhibitor for the Treatment of Mature B-Cell Malignancies. (Pubmed Central) - Oct 13, 2025 Multiparameter optimization allowed efficient prioritization of molecules with good potency and drug-like properties during lead optimization, which led to the discovery of a highly potent MALT1 inhibitor, SGR-1505, with a well-balanced property profile. It demonstrated strong antitumor activity alone and in combination with BTK inhibitor in multiple in vivo B-cell lymphoma xenograft models and progressed to a phase 1 clinical trial in patients with mature B-cell neoplasms.
- |||||||||| Bioengineering Synthetic Lymphoma Models: Advancements in Ex Vivo Systems (OCCC - West Hall E2; Virtual; In-Person) - Sep 18, 2025 - Abstract #ASH2025ASH_535;
These models have revealed that Ly-TME-derived factors, including extracellular matrix and T cell help, amplify oncogenic signaling through the BCR-MYD88-TLR9 supercomplex, reducing the efficacy of targeted therapies such as BTK and MALT1 inhibitors, and combinatorial inhibition strategies to overcome roadblocks in therapeutic responses. Furthermore, he will discuss the implementation of advanced imaging to study tumor and T cell interfaces, how it regulates epigenetics of lymphoma cells via chromatin remodeling, contributing to poor response to therapies.
- |||||||||| Review, Journal, IO biomarker: Chronic Lymphocytic Leukemia: Novel Therapeutic Targets Under Investigation. (Pubmed Central) - Jul 29, 2025
This review provides an in-depth overview of the promising novel treatment approaches under investigation in CLL, focusing on advanced cellular therapies (CAR T-cell therapy), T-cell engagers, new monoclonal antibodies, and various next-generation small molecule inhibitors including BTK degraders, PI3K inhibitors, MALT1 inhibitors, c-MYC inhibitors, CDK9 inhibitors, and agents targeting angiogenesis and DNA damage repair. In this review, we will discuss the novel therapeutic targets and agents as well as ongoing trials, emphasizing the potential of these treatments to overcome resistance and meet the unmet needs of patients, particularly those with double-refractory CLL.
- |||||||||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Preclinical, Journal: Telaprevir attenuates caspase-11-dependent pyroptosis in mouse heart following ischemia/reperfusion via inhibition of MALT1/TRAF6 pathway. (Pubmed Central) - Jul 17, 2025 Mechanistically, telaprevir inhibited the recruitment of TRAF6 by MALT1, concomitant with the reduced recruitment of caspase-11 by TRAF6, and in turn, attenuated caspase-11?K63 poly-ubiquitination and activation, which was further confirmed by knockdown of TRAF6. Based on these results, we concluded that telaprevir could protect mouse heart against I/R injury by reducing caspase-11-dependent pyroptosis through inhibition of MALT1/TRAF6 pathway.
- |||||||||| Targeting Tumor Cell MALT1 Reprograms Tumor Microenvironment via Macrophage M1 Polarization and Overcomes Radioresistance in NSCLC (Screen: 3; Hall F) - Jul 7, 2025 - Abstract #ASTRO2025ASTRO_1956;
Our study establishes that combining radiotherapy with MALT1 inhibitors suppresses the CD73-adenosine axis and promotes M1 macrophage polarization, thereby reprogramming the tumor microenvironment. These findings identify MALT1 as a clinically significant prognostic biomarker for NSCLC patients undergoing radiotherapy and demonstrate that therapeutic targeting of MALT1 synergistically enhances radiation efficacy through microenvironmental immune modulation.
- |||||||||| Journal: Novel MALT1 Inhibitors for Treating Cancer. (Pubmed Central) - Jun 18, 2025
Active, not recruiting --> Completed Provided herein are novel MALT1 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.
- |||||||||| Review, Journal: An updated patent review of MALT1 inhibitors (2021-present). (Pubmed Central) - Jun 1, 2025
We still lack potent and selective competitive or covalent MALT1 inhibitors, indicating the challenges with targeting the active site. Further, MALT1 protein degraders and MALT1 scaffolding inhibitors have been developed, which may have distinct inhibitory profiles compared to allosteric MALT1 protease inhibitors, but more potent and selective compounds are needed to judge the feasibility and usefulness of these approaches.
- |||||||||| MicroRNAs TARGET TUMOR SUPPRESSOR GRK2 IN MALT1-DEPENDENT DIFFUSE LARGE B-CELL LYMPHOMA () - May 4, 2025 - Abstract #ICML2025ICML_187;
We find that inhibitors of these miRNAs enhance GRK2 expression and thereby suppress MALT1 activity and MALT1-dependent tumor cell proliferation, both in vitro and in vivo. These studies suggest that microRNA inhibitors which enhance GRK2 expression could represent a novel approach for restraining MALT1-dependent lymphomagenesis.
- |||||||||| Journal: A small-molecule inhibitor of BCL10-MALT1 interaction abrogates progression of diffuse large B cell lymphoma. (Pubmed Central) - Apr 15, 2025
We report the identification of M1i-124 as a first-in-class compound that blocks BCL10-MALT1 interaction, abrogates MALT1 scaffolding and protease activities, promotes degradation of BCL10 and MALT1 proteins, and specifically targets ABC-DLBCLs characterized by dysregulated MALT1. Our findings demonstrate that small-molecule inhibitors of BCL10-MALT1 interaction can function as potent agents to block MALT1 signaling in selected lymphomas, and provide a road map for clinical development of a new class of precision-medicine therapeutics.
- |||||||||| safimaltib (JNJ-6633) / J&J, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion: A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL (clinicaltrials.gov) - Mar 31, 2025 P1, N=45, Completed, Our findings demonstrate that small-molecule inhibitors of BCL10-MALT1 interaction can function as potent agents to block MALT1 signaling in selected lymphomas, and provide a road map for clinical development of a new class of precision-medicine therapeutics. Active, not recruiting --> Completed
- |||||||||| SY-12696 / Shouyao Holdings
SY-12696, a novel and potent MALT1 protease inhibitor, for the treatment of B-cell lymphomas (Section 21; Poster Board No: 3) - Mar 25, 2025 - Abstract #AACR2025AACR_5637; Active, not recruiting --> Completed Based on current studies, SY-12696 has demonstrated significant inhibitory potency on ABC-DLBCL cancer cells in vitro and in vivo, which makes SY-12696 a promising candidate for further development as a monotherapy or in combination with BTKi to treat relapsed/refractory B-cell lymphoma, particularly those resistance to BTKi.
- |||||||||| bleomycin / Generic mfg.
Succinate-mediated Activation of the GPR91/MALT1/NF-?B/CCL2 Pathway in Macrophages Contributes to Pulmonary Fibrosis (Area L, Hall F (North Building, Exhibition Level), Moscone Center; Poster Board # P1386) - Mar 16, 2025 - Abstract #ATS2025ATS_9311; Result Dimethyl Malonate (DMM), a succinate inhibitor, mitigates pulmonary fibrosis in bleomycin-challenged mice...Conclusion Succinate triggers CCL2 release in macrophages via the GPR91/MALT1/NF-?B pathway, worsening pulmonary fibrosis. It may represent a promising target for therapeutic intervention in pulmonary fibrosis.
- |||||||||| Review, Journal: MALT1 Inhibitors and Degraders: Strategies for NF-?B-Driven Malignancies. (Pubmed Central) - Feb 25, 2025
This Perspective provides an overview of MALT1's structural and functional characteristics, summarizes recent advancements in small-molecule inhibitors and degraders targeting this protein, and discusses compound structures, structure-activity relationship (SAR) analyses, and biological activities. We aim to inform future research efforts to enhance the activity, selectivity, and pharmacological properties of MALT1-targeting compounds, establishing a foundational framework for drug development in this critical area of cancer therapy.
|